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a b s t r a c t
Middle East respiratory syndrome coronavirus (MERS-CoV) infects host cells through binding the
receptor binding domain (RBD) on its spike glycoprotein to human receptor dipeptidyl peptidase 4
(hDPP4). Here, we report identiﬁcation of critical residues on hDPP4 for RBD binding and virus entry
through analysis of a panel of hDPP4 mutants. Based on the RBD–hDPP4 crystal structure we reported,
the mutated residues were located at the interface between RBD and hDPP4, which potentially changed
the polarity, hydrophobic or hydrophilic properties of hDPP4, thereby interfering or disrupting their
interaction with RBD. Using surface plasmon resonance (SPR) binding analysis and pseudovirus infection
assay, we showed that several residues in hDPP4–RBD binding interface were important on hDPP4–RBD
binding and viral entry. These results provide atomic insights into the features of interactions between
hDPP4 and MERS-CoV RBD, and also provide potential explanation for cellular and species tropism of
MERS-CoV infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Middle East respiratory syndrome (MERS), a novel coronavirus
which causes severe respiratory illness, was ﬁrst reported in
a patient from Saudi Arabia in 2012 (de Groot et al., 2013).
To date, individual cases as well as small clusters and large
outbreaks have been reported in several countries and the
mortality rate is estimated at 30% among laboratory-conﬁrmed
cases (Organization, 2014). Phylogenetic analysis demonstrates
that the MERS coronavirus (MERS-CoV) is genetically closest to
clade 2c betacoronavirus found in camels and insectivorous bats
(Ithete et al., 2013) although the true viral reservoir remains
uncertain. The clinical symptoms caused by MERS-CoV are similar
to those caused by severe acute respiratory syndrome coronavirus
(SARS-CoV) although the two viruses use two distinct receptors;
MERS-CoV uses dipeptidyl peptidase 4 (DPP4) while SARS-CoV
uses angiotensin-converting enzyme 2 (ACE2). Other corona-
viruses use other receptors and perhaps this provides partial
explanation for their cellular and species tropism. MERS-CoV can
replicate in a range of cell lines derived from human, non-human
primate, porcine, and bat (de Wit et al., 2013). Traditional small
laboratory animals, such as mice (Coleman et al., 2014), hamsters
(de Wit et al., 2013), and ferrets (Raj et al., 2014), were shown to
resist MERS-CoV infection. The ﬁnite host range of MERS-CoV has
seriously restricted the development of appropriate animal models
to study the pathogenesis of this virus and to assess the efﬁcacy of
potential therapeutic strategies. Raj et al. (2014) demonstrated
that human receptor DPP4 (hDPP4) domain (residues 246 to 505)
could confer the susceptibility of ferret DPP4 to MERS-CoV infec-
tion. Zhao et al. (2014) are the ﬁrst to describe a method of
developing a small-animal model for MERS-CoV in which an
adenovirus expressing hDPP4 was utilized to transiently transduce
mouse airway cells and make mice susceptible to MERS-CoV
infection. Recently van Doremalen et al. (2014) showed that
DPP4 played an important role in the observed species tropism
of MERS-CoV infection and identiﬁed residues in DPP4 responsible
for this restriction. These results indicate that the insusceptibility
to infection is primarily determined by the inability of MERS-CoV
binding to DPP4 of a non-permissive cell line.
Previous ﬁndings have shown that hDPP4 extracellular domain
consists of a variable N-terminal eight-blade β-propeller domain
and a conserved C-terminal α/β-hydrolase domain (Engel et al.,
2003; Rasmussen et al., 2003). However, our understanding of
critical residues of hDPP4 on MERS-CoV interaction and entry
is quite limited. We and others have previously characterized
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RBD–hDPP4 crystal structure (Chen et al., 2013; Lu et al., 2013;
Wang et al., 2013). The RBD–hDPP4 crystal structure showed that
the viral RBD recognized blades IV and V of the DPP4 β-propeller
domain. The atomic interaction details of the binding interface
revealed that the RBD receptor recognition was predominantly
mediated by several amino-acid residue interactions, including
RBD residue D539 with DPP4 residue K267, RBD Y499 with DPP4
R336, RBD residues D510 and E513 with DPP4 residues R317 and
Q344, RBD L506, W553 and V555 with DPP4 L294 and I295.
Previously, we have generated a panel of MERS-CoV mutant RBD
proteins at the residues D539, Y499, D510, E513, L506, W553 and
V555 to characterize their impacts on binding activity to hDPP4
and the entry efﬁciency into target cells. However, the impacts of
the corresponding residues on hDPP4 have not been well char-
acterized. Here, through structure-guided mutagenesis, we identi-
ﬁed several key residues in hDPP4 that were critical for RBD
binding measured by both real-time surface plasmon resonance
(SPR) and pseudovirus entry. These residues included K267 and
R336 on binding patch 1, and L294, I295, R317 and Q344 on
binding patch 2. The mutations of three positively charged
residues K267, R336 and R317 perhaps interfere with the interac-
tion of the negatively charged residues on the surface of RBD; the
mutations of L284, I295 and Q344 may lead to the change of
hydrophobic or hydrophilic properties of hDPP4 at the interface
with RBD.
Results
Critical residues on hDPP4 for binding to MERS-CoV RBD
Our previous ﬁndings have shown that the binding interface
between hDPP4 and MERS-CoV RBD is mainly composed of two
binding patches, patch 1 and patch 2 (Fig. 1A). The patch 1 interface
is characterized by interactions between C-terminal end of the
long linker connecting the RBD β6/β7 strands and the hDPP4 blade
4. The contact in patch 1 is critically determined by the polar
interactions among a group of hydrophilic amino-acid residues,
including RBD E536, D537, D539 and Y499 and hDPP4 K267 and
R336. In this patch, DPP4 residue K267 interacts with RBD D539 by
salt bridge (Fig. 1B), while DPP4 residue R336 forms hydrogen
bond with RBD residue Y499 (Fig. 1C). Patch 2 has a hydrophobic
core surrounded by a hydrophilic periphery. In the hydrophobic
core, RBD and hDPP4 contacts are critically dependent on a few
‘hot spot’ residues including RBD L506, W553 and V555, and DPP4
L294 and I295. However, the surrounding hydrophilic surface
consists of RBD residues D510, E513 and Y540, and DPP4 residues
H298, R317 and Q344. Among these hydrophilic residues, the salt
bridge and hydrogen bond between D510 and R317, E513 and
Q344 contribute to the maintenance of RBD-receptor contact
(Fig. 1D).
To study the impacts of the substitutions of the critical residues
on hDPP4 described above on the interaction between MERS-CoV
RBD and hDDP4, we determined the binding efﬁciency between
these two proteins by employing SPR technique. First, we con-
structed a series of hDPP4 mutants guided by the RBD–hDPP4
complex crystal structure information (Wang et al., 2013). The
wide-type and mutant hDPP4 were introduced into baculovirus
expression system. All wide-type and mutant forms of hDPP4
were expressed efﬁciently (data not shown). Second, the binding
efﬁciency was measured by SPR. As shown in Fig. 2 and Table 1,
mutations at several hDPP4 residues, in individual or combination,
resulted in a signiﬁcant attenuation in binding to MERS-CoV RBD.
In patch 1, residue K267 mutation (K267A and K267E) presumably
damaged the salt-bridge interaction, completely abrogated the
binding between hDPP4 and RBD, while R336A reduced RBD and
hDPP4 binding about 100 fold. In patch 2, double mutations at
L294 and I295 (L294Aþ I295A and L294Dþ I295D) completely
eliminated the binding between RBD and hDPP4, presumably by
disrupting hydrophobic interactions with RBD L506, W553 and
V555. In contrast, the single-residue substitution of R317A and
Q344A in the hydrophilic surface of patch 2 had negligible effect
on binding efﬁciency.
Key residues on hDPP4 for MERS-CoV pseudovirus entry into target
cells
To further study the importance of the critical residues on
hDPP4 on viral entry, we measured the entry efﬁciency of
pseudovirus into COS7 cells expressing the wide-type and mutant
forms of hDPP4. The expression levels of the wide-type and
mutant hDPP4 were analyzed by ﬂuorescence-activated cell sort-
ing (FACS) using goat anti-hDPP4 polyclonal antibody. All of the
wide-type and mutant hDPP4 proteins could be expressed on the
surface of COS7 cells with the similar expression efﬁciency
(Fig. 3A). Forty-eight hours later, these cells were exposed to
pseudovirus infection and their entry efﬁciency was measured by
luciferase activity 48 h later. As showed in Fig. 3B, the residue
mutations located at patch 1 (K267A, K267E and R336A) and
hydrophobic region of patch 2 (L294Aþ I295A and L294Aþ I295D)
Fig. 1. The amino-acid residue interaction details at the binding interface. (A) Two patches of the binding interface. Patch 1 interface is characterized by interactions between
the C-terminal end of the long linker connecting the RBD β6/β7 strands (light magenta) and the hDPP4 blade 4 (cyan). In patch 2, a gently concaved outer surface in RBD
(light magenta) accommodates a linker containing a short α helix between hDPP4 blades 4 and 5 (cyan). (B) and (C) Hydrophilic residues of RBD and hDPP4 interact through
polar contacts in patch 1. RBD D539 has salt-bridge interaction with hDPP4 residue K267 (B). DPP4 residue R336 forms hydrogen bond with RBD residue Y499 (C). The polar
contacts (salt-bridge and hydrogen bond) are drawn as black dashed sticks. (D) Hot spot residues in the hydrophobic core and hydrophilic periphery of patch 2.
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resulted in signiﬁcantly reduction in viral entry. This is consistent
with the binding results described previously. In the hydrophilic
region of patch 2, residue substitution R317 led to partial loss of
viral infection (41.4%), while the mutation Q344 modestly
increased viral infection (22.8%).
Discussion
In summary, we have identiﬁed several key residues in hDPP4
critical for viral binding and entry into target cells. These residues
include positively charged residues of patch 1 (K267 and R336)
and hydrophobic zone of patch 2 (L294 and I295). In contrast, the
mutations at hydrophilic zone of patch 2 (R317 and Q344) had
little inﬂuence on binding and virus entry efﬁciency. These results
showed that the positively charged residues at the outer surface of
blade 4 and the hydrophobic regions of blade 5 may play an
important role in mediating viral binding and entry into the target
cells, while the impact of mutations at hydrophilic region of patch
2 was barely detectable. This is consistent with our earlier ﬁndings
(Wang et al., 2013) where residue mutations at the corresponding
negatively charged and hydrophobic core positions on RBD of
MERS-CoV could signiﬁcantly reduce both binding and viral entry
efﬁciency.
Sequence analysis of DPP4 from multiple animal species (Fig. 4)
showed that MERS-CoV susceptible animals, such as macaque,
camel and bat, shared the same sequence with hDPP4 at blades IV
and V. In contrast, those MERS-CoV resistant animals, such as
mouse, rat and ferret, have residues at L294, I295 and R366 that
are all different from hDPP4. Raj et al. (2014) reported that when
these sites of hDPP4 were changed to the residues of ferret, the
binding and viral infection efﬁciency could also be decreased.
van Doremalen et al. (2014) found 5 residues involved in the
hDPP4–RBD interaction which were important to determine the
susceptibility to MERS-CoV infection, in which I295 and R336 were
included. These results are consistent with our ﬁndings and
suggest these residues play an important role in RBD binding
and viral entry, and determining the tropism to MERS-CoV
infection.
Materials and methods
Constructs and protein expression
MERS-CoV RBD (residues 367-606) and the extracellular
domain of hDPP4 (residues 39-766) were expressed using a Bac-
to-Bacs baculovirus expression system (Invitrogen). In brief, the
DNA encoding RBD and hDPP4 were respectively cloned into the
pFastBac™ dual vector (Invitrogen) incorporating an N-terminal
gp67 signal peptide to facilitate secretion and a C-terminal hexa
histidine-tag for puriﬁcation. The constructed DNA was then
transformed into the bacterial DH10Bac competent cells and the
recombined bacmid DNA was extracted and transfected into Sf9
cells using Cellfectin II Reagent (Invitrogen). After 5–7 days of
incubation at 300 K, the low-titer viruses were harvested and then
ampliﬁed. The ampliﬁed high-titer viruses were then used to
infect Sf9 cells and the cell culture supernatant containing target
protein was harvested 60 h after infection, concentrated, loaded to
nickel (Ni)-charged resin (GE Healthcare), and eluted with 0.5 M
imidazole and further puriﬁed using the Superdex™ 200 high-
performance column (GE Healthcare) pre-equilibrated with Tris
Fig. 2. SPR assay for afﬁnity binding between RBD and wide-type or mutant hDPP4. hDPP4 and its mutants (R336A, R317A, Q344A, K267A, K267E, L294Aþ I295A,
L294Dþ I295D) were injected at a series of concentrations (shown on the right of the respective proﬁle) in a buffer containing 10 mM HEPES, pH 7.2, 150 mM NaCl, and
0.005% (v/v) Tween-20. The kinetic ﬁts are shown in blue.
Table 1
Summary of SPR and viral entry efﬁciency.
Location Mutations Afﬁnity
(Kd, M)
Relative value of viral entry
(% of WT)
Wild type 1.2E08 100.0
Patch 1 K267A No binding 1.4
K267E No binding 0.3
R336A 1.1E06 6.6
Patch 2
Hydrophobic
zone
L294Aþ I295A No binding 0.3
L294Dþ I295D No binding 0.5
Hydrophilic
zone
R317A 7.7E07 41.4
Q344A 2.3E08 122.8
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buffer (50 mM Tris, pH 8.8, 40 mM NaCl). Fractions containing the
puriﬁed protein were collected and applied directly to a pre-
equilibrated Resource™ Q column (GE Healthcare) and then eluted
with a 0.05–1 M NaCl gradient in 40 mM Tris buffer (pH 8.8).
Fractions containing protein were ﬁnally puriﬁed using Super-
dex™ 200 column pre-equilibrated with HBS (10 mM HEPES, pH
7.2, 150 mM NaCl) and centrifuged to 1 mg/ml. Mutants of the
extracellular domain of hDPP4 were constructed using a stan-
dard PCR-based cloning strategy. And the mutant proteins were
expressed and puriﬁed in the same way.
SPR analysis
The SPR analyses were carried out using a Biacore T200
instrument (GE Healthcare) equipped with a research-grade CM5
sensor chip. To measure the afﬁnity binding between RBD and
wide-type or mutant hDPP4, the RBD was immobilized on the
sensor chip by standard amine coupling procedure. The ﬂow cell
1 was left blank to serve as a reference. Puriﬁed RBD at a con-
centration of 5 μg/ml in sodium acetate buffer (10 mM, pH 5.0)
was immobilized to a density of 300–400 response units on the
ﬂow cell 2. For the collection of binding data, hDPP4 or its mutants
in a buffer of 10 mM HEPES, pH 7.2, 150 mM NaCl, and 0.005% (v/v)
Tween-20 were injected over the two ﬂow cells at a series of
concentration at a 30 μl/min ﬂow rate and 298 K. The RBD–hDPP4
complex was allowed to associate for 60 s and dissociated for 60 s.
The surfaces were regenerated with an injection of 5 mM NaOH
between each cycle if needed. The data was analyzed with the
Biacore T200 evaluation software by ﬁtting to a 1:1 Langmuir
binding model.
MERS-CoV pseudovirus and viral infection
MERS-CoV pseudovirus was generated by co-transfection of
human immunodeﬁciency virus (HIV) backbone expressing ﬁreﬂy
luciferase (pNL43R-E-luciferase) and MERS-CoV spike glycoprotein
expression vector (pcDNA3.1þ , Invitrogen) into the 293 T cells.
Viral supernatants were harvested 48 h later, normalized by p24
ELISA kit (Beijing Quantobio Biotechnology Co., LTD, China) before
infecting the target COS7 cells transiently expressing wide-type or
mutant hDPP4. The wide-type and mutant hDPP4 expressing COS7
cells were incubated with goat anti-hDPP4 polyclonal antibody
(R&D) followed by incubation with ﬂuorescein phycoerythrin (PE)-
labeled rabbit anti-goat IgG antibody (Santa Cruz). The expression
levels of wide-type and mutant hDPP4 were measured by ﬂow
cytometer (BD Aria II) and the mean ﬂuorescence intensity (MFI)
was analyzed. The COS7 cells infected by MERS-CoV pseudovirus
were lysed at 48 h post infection and viral entry efﬁciency was
quantiﬁed by comparing the luciferase activity between pseudo-
viruses-infected COS7 cells expressing wide-type and those
infected COS7 cells expressing mutant hDPP4.
Fig. 4. Amino acid sequence alignment of DPP4 blades IV and V from different species. The mutated positions are highlighted in red boxes.
Fig. 3. Infection efﬁciency of MERS-CoV pseudoviruses into COS7 cells expressing wide-type or mutant hDPP4. (A) hDPP4 expression on COS7 cells. COS7 cells transiently
transfected with different hDPP4 constructs were used as target cells for pseudovirus infection. The mean ﬂuorescence intensity (MFI) of target cells and control cells
(without hDPP4 transfection) incubated with ﬂuorescent antibody was determined by ﬂow cytometer. The result shown is representative of three independent experiments
conducted in triplicate. The actual residue mutants in hDPP4 are indicated below the horizontal axis. (B) The entry efﬁciency (%) of pseudovirus was calculated on the basis of
luciferase activity. And the percentages of pseudovirus entry efﬁciency shown for mutant hDPP4 were luciferase activity values versus that of the wide-type hDPP4, as the
entry efﬁciency for wide-type hDPP4 was deﬁned as 100%. Data shown were corrected for the expression of different hDPP4 constructs by the parameter of MFI. Error bars
represent standard errors of the means of three independent experiments. Student’s t-test; nPo0.05; nnPo0.01.
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